A. HISTORY AND DEVELOPMENT OF THE COMPANY Novo Nordisk A/S was formed in 1989 by a merger of two Danish companies, Nordisk Gentofte A/S and Novo Industri A/S. Novo Industri A/S was the continuing company and its name was changed to Novo Nordisk A/S. The business activities of Nordisk Gentofte were established in 1923 by August Krogh, H. C. Hagedorn and A. Kongsted, and the business activities of Novo Industri A/S were established in 1925 by Harald and Thorvald Pedersen. From the beginning, the business of both companies was the production and sale of insulin for the treatment of diabetes. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (NOVO-B). Its ADRs are listed on the New York Stock Exchange (NVO). Reference is made to ‘More information', on page 131 of our Annual Report 2025 for information on domicile. 4 Important events in 2025 Reference is made to ‘Introducing Novo Nordisk’, pages 3-11 and ‘2025 performance and 2026 outlook’, pages 14-17 of our Annual Report 2025 for a description of important events in 2025.